Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

When MRI offered no clear answer in suspected prostate cancer, the use of prostate-specific membrane antigen (PSMA)-PET/CT showed promise for reducing the number of biopsies without compromising the ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...

Early-stage prostate cancer rarely causes symptoms, making routine screening the most reliable way to catch it before it ...

Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research.

Almost 50 men recorded a ‘red’ reading in a recent prostate cancer testing held in Burnley. From 392 samples taken, 47 ...

Prostate cancer screening compares favorably to screening for breast cancer in identifying significant cancers, reducing ...